Mar. 13 2024
Source Page: Scottish Health Survey and health record dataFound: Note there is a time lag of up to a year with cancer records so these will not be complete.NRS Deaths
Mar. 11 2024
Source Page: Equity in medical devices: independent review - final reportFound: Imaging databanks for skin cancer diagnostic devices 6.
Mar. 11 2024
Source Page: Equity in medical devices: independent review - final reportFound: Imaging databanks for skin cancer diagnostic devices 6.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to tackle regional variations in early diagnosis of ovarian cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is taking a wide range of activity to increase awareness and early diagnosis of, as well as tackle regional variations in, ovarian cancer. Since 2020 NHS England has run several Help Us Help You campaigns, that have included a focus on abdominal symptoms which, amongst other abdominal cancers, can be indicative of ovarian cancer.
NHS England relaunched the Help Us Help You cancer campaign on the 8 January 2024, to encourage people to get in touch with their general practitioner if they notice, or are worried about, symptoms that could be cancer. The campaign address barriers to people coming forward with suspected signs of cancer in general, and is not specific to ovarian cancer.
Raising awareness and improving early diagnosis of cancers, including ovarian cancer, remains a priority across all regions in England. NHS England is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that, from 2028, around 55,000 more people each year will survive their cancer for at least five years after diagnosis.
To help increase cancer diagnosis rates, as of February 2024, there are 154 community diagnostic centres (CDCs) open with over six million checks carried out, with the aim of having 160 CDCs open by March 2025. We also plan to transform the way the National Health Service provides elective care, by increasing activity at dedicated and protected surgical hubs. These will help separate elective care facilities from urgent and emergency care, including for ovarian cancer. At present, the surgical hubs are focusing on a number of specialities, including gynaecology.
The NHS is improving pathways to get people diagnosed faster once they are referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 108 NSS pathways are currently operational, with more in development.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase awareness of ovarian cancer symptoms.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is taking a wide range of activity to increase awareness and early diagnosis of, as well as tackle regional variations in, ovarian cancer. Since 2020 NHS England has run several Help Us Help You campaigns, that have included a focus on abdominal symptoms which, amongst other abdominal cancers, can be indicative of ovarian cancer.
NHS England relaunched the Help Us Help You cancer campaign on the 8 January 2024, to encourage people to get in touch with their general practitioner if they notice, or are worried about, symptoms that could be cancer. The campaign address barriers to people coming forward with suspected signs of cancer in general, and is not specific to ovarian cancer.
Raising awareness and improving early diagnosis of cancers, including ovarian cancer, remains a priority across all regions in England. NHS England is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that, from 2028, around 55,000 more people each year will survive their cancer for at least five years after diagnosis.
To help increase cancer diagnosis rates, as of February 2024, there are 154 community diagnostic centres (CDCs) open with over six million checks carried out, with the aim of having 160 CDCs open by March 2025. We also plan to transform the way the National Health Service provides elective care, by increasing activity at dedicated and protected surgical hubs. These will help separate elective care facilities from urgent and emergency care, including for ovarian cancer. At present, the surgical hubs are focusing on a number of specialities, including gynaecology.
The NHS is improving pathways to get people diagnosed faster once they are referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 108 NSS pathways are currently operational, with more in development.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to increase early diagnosis of ovarian cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is taking a wide range of activity to increase awareness and early diagnosis of, as well as tackle regional variations in, ovarian cancer. Since 2020 NHS England has run several Help Us Help You campaigns, that have included a focus on abdominal symptoms which, amongst other abdominal cancers, can be indicative of ovarian cancer.
NHS England relaunched the Help Us Help You cancer campaign on the 8 January 2024, to encourage people to get in touch with their general practitioner if they notice, or are worried about, symptoms that could be cancer. The campaign address barriers to people coming forward with suspected signs of cancer in general, and is not specific to ovarian cancer.
Raising awareness and improving early diagnosis of cancers, including ovarian cancer, remains a priority across all regions in England. NHS England is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that, from 2028, around 55,000 more people each year will survive their cancer for at least five years after diagnosis.
To help increase cancer diagnosis rates, as of February 2024, there are 154 community diagnostic centres (CDCs) open with over six million checks carried out, with the aim of having 160 CDCs open by March 2025. We also plan to transform the way the National Health Service provides elective care, by increasing activity at dedicated and protected surgical hubs. These will help separate elective care facilities from urgent and emergency care, including for ovarian cancer. At present, the surgical hubs are focusing on a number of specialities, including gynaecology.
The NHS is improving pathways to get people diagnosed faster once they are referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 108 NSS pathways are currently operational, with more in development.
Asked by: McMillan, Stuart (Scottish National Party - Greenock and Inverclyde)
Question
To ask the Scottish Government whether it will offer free BRCA gene testing to anyone living in Scotland aged 18 or over with one or more Jewish grandparents, of any type of Jewish origin, in a similar way to NHS England's Jewish BRCA Testing Programme, in light of the reported finding that having a BRCA gene fault is associated with an increased risk of developing certain types of cancer, particularly breast, ovarian, prostate and pancreatic cancer.
Answered by Gray, Neil - Cabinet Secretary for NHS Recovery, Health and Social Care
As set out in answer to question S6W-25450 on 27 February 2024, NHS Scotland currently offers a whole gene screening panel for hereditary breast and ovarian cancer to test for faults in both BRCA1 and BRCA2 and a range of other target genes. At present, this testing is available to people from specific population groups (including those of Ashkenazi Jewish heritage) if they meet clinical criteria that indicate a higher genetic risk of breast and ovarian cancer.
The Scottish Strategic Network for Genomic Medicine (SSNGM) was established in 2022 to develop a fully considered and sustainable genomic medicine service for Scotland. The SSNGM contains specialist Scottish Genomics Test Advisory Groups (SG-TAG) for both cancer and rare and inherited conditions, whose role is to review and assess the clinical validity and utility of new tests, and changes to the referral criteria for existing tests.
The SSNGM plan to initiate a review of the existing hereditary cancer testing pathways in 2024. This review will include both the referral criteria for our existing genomic test offering and alternative testing methods and will make recommendations via the SG-TAG process.
All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .
Asked by: Lennon, Monica (Scottish Labour - Central Scotland)
Question
To ask the Scottish Government whether it will consider offering BCRA testing to NHS Scotland patients with Jewish ancestry, in light of NHS England establishing a national BRCA gene-testing programme for such patients.
Answered by Gray, Neil - Cabinet Secretary for NHS Recovery, Health and Social Care
NHS Scotland currently offers a whole gene screening panel for hereditary breast and ovarian cancer to test for faults in both BRCA1 and BRCA2 and a range of other target genes. At present, this testing is available to people from specific population groups (including those of Ashkenazi Jewish heritage) if they meet clinical criteria that indicate a higher genetic risk of breast and ovarian cancer.
The Scottish Strategic Network for Genomic Medicine (SSNGM) was established in 2022 to develop a fully considered and sustainable genomic medicine service for Scotland. The SSNGM contains specialist Scottish Genomics Test Advisory Groups (SG-TAG) for both cancer and rare and inherited conditions, whose role is to review and assess the clinical validity and utility of new tests, and changes to the referral criteria for existing tests.
The SSNGM plan to initiate a review of the existing hereditary cancer testing pathways in 2024. This review will include both the referral criteria for our existing genomic test offering and alternative testing methods and will make recommendations via the SG-TAG process.
Oral Evidence Jan. 29 2024
Inquiry: Future cancerFound: in cancer screening.
Asked by: Chloe Smith (Conservative - Norwich North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the rollout of community diagnostic centres on the time taken to diagnose less survivable cancers.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Government is taking steps through NHS England to improve outcomes for cancer patients, including those cancers mentioned by the Less Survivable Cancer Taskforce, namely lung, liver, brain, oesophageal, pancreatic and stomach. Diagnostic checks are a key part of cancer pathways and the 150 community diagnostic centres (CDCs) opened by the Government will give earlier diagnostic tests, benefitting millions of patients including those who are referred with suspected less survivable cancers. National Health Service systems have been asked to prioritise CDC capacity towards their most challenged cancer pathways, where this is clinically appropriate, and these centres have delivered over six million additional tests for all elective activity since July 2021. The CDC programme is on track to meet its target to open up to 160 CDCs by March 2025, with many due to open ahead of schedule.
In November 2022, the NHS also announced an expansion of direct access to diagnostic scans across all general practices, to help cut waiting times and speeding up cancer diagnosis, or all-clear for patients. The NHS is now looking to widen the clinical pathways for which this is offered.
Making improvements across different cancer types is critical to helping achieve the NHS Long Term Plan ambition of diagnosing 75% of patients at an early stage by 2028 and reducing inequalities in cancer survival. NHS England has commissioned new cancer clinical audits covering six cancer types, some of which are less survivable: pancreatic cancer, ovarian cancer, non-Hodgkin lymphoma, kidney cancer and primary and metastatic breast cancer. All six audits will cover care delivered in England and Wales.